FIELD: measurement; testing.
SUBSTANCE: invention involves comparing the expression level of the tropomyosin isoform P09493-3 in a sample from a patient with a control value where increasing the expression level of P09493-3 is an indicator of AD or MCI.
EFFECT: invention relates to a method for detecting patients with suspected Alzheimer's disease (AD) or moderate cognitive impairment (MCI) in vitro.
6 cl, 3 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| LACTOFERRIN, USED IN DIAGNOSING OR PREDICTING ALZHEIMER'S DISEASE OR DIAGNOSING PARKINSON'S DISEASE | 2016 |
|
RU2745602C2 |
| ANTIBODY, WHICH RECOGNIZES PEPTIDE T14 ACHE | 2016 |
|
RU2729491C2 |
| METHODS OF TREATING ALZHEIMER'S DISEASE | 2015 |
|
RU2720468C2 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING ALZHEIMER'S DISEASE USING A PANEL OF BLOOD PROTEINS | 2021 |
|
RU2794040C1 |
| ANTIBODIES, SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2727911C2 |
| ANTIBODIES SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2760875C1 |
| HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE | 2020 |
|
RU2783528C1 |
| METHOD FOR DETERMINATION OF APOLIPOPROTEIN E4 | 2017 |
|
RU2779197C2 |
| COMPOSITION CONTAINING ANTIBODY AGAINST ABETA PROTOFIBRILS AND INHIBITOR OF BETA-SECRETASE BACE1 FOR TREATMENT OF ALZHEIMER'S DISEASE | 2017 |
|
RU2786476C2 |
| ANTI-AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES POSSESSING THERAPEUTIC PROPERTIES | 2006 |
|
RU2551782C2 |
